Ignite Creation Date:
2025-12-24 @ 2:59 PM
Ignite Modification Date:
2025-12-28 @ 10:04 PM
Study NCT ID:
NCT04739059
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-08-19
First Post:
2021-02-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
Sponsor:
CSL Behring
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CSL312_3002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None